Arcus Biosciences Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Arcus Biosciences's estimated annual revenue is currently $37.9M per year.(i)
  • Arcus Biosciences received $107.0M in venture funding in November 2017.
  • Arcus Biosciences's estimated revenue per employee is $72,271
  • Arcus Biosciences's total funding is $647.1M.
  • Arcus Biosciences's current valuation is $2.5B. (January 2022)

Employee Data

  • Arcus Biosciences has 524 Employees.(i)
  • Arcus Biosciences grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Arcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world's largest biotechnology research hub. Unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. For this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. Arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. These new drugs will then be deployed in various combinations to combat cancer. We are growing very actively and are always interested in hearing from scientists with a recent PhD in Chemistry, Immunology and one of the quantitative life sciences (Biochemistry, Enzymology, Molecular Pharmacology, etc). We also have openings for experienced researchers with ten or more years assay development experience applied either in the context of SAR support or clinical PD marker assays. If this describes you, please check out the opportunities on our website at



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Arcus Biosciences News

2022-04-13 - Arcus Biosciences Announces New Employment Inducement ...

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for...

2022-04-06 - Arcus Biosciences Shares Rise 12% After Addition to S&P SmallCap 600

By Chris Wack. Arcus Biosciences Inc. shares rose 12% to $39.15 after S&P Dow Jones Indices added it to the S&P SmallCap 600.

2022-03-30 - Arcus Biosciences gains 10% on addition to SmallCap 600

Arcus Biosciences (NYSE:RCUS) has jumped 9.7% postmarket on the news it's set to join the S&P SmallCap 600 index. It's moving in to replace...

2021-03-09 - Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Mar 9, 2021-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees opt ...

2021-02-24 - Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights

HAYWARD, Calif.--(BUSINESS WIRE)--Feb 24, 2021-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided operational ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Arcus Biosciences Funding

DateAmountRoundLead InvestorsReference
2016-08-31$70.0MBArcus Biosciences IncArticle